Capital Flow Monitor · Sponsors · CIK 1981267
LumaBio I LP
595 MADISON AVENUE 31ST FLOOR, NEW YORK, NY, 10022 · 917-859-9186
Pooled Investment Fund / Venture Capital Fund · Limited Partnership· inc. CAYMAN ISLANDS true 2022
Fit score
—
Offering
—
Sold
$410.0M
% sold
—
Investors
63
Min investment
$0
Exemption
506(b)
Filing history
| Filed | Form | Rule | Offering | Sold | % sold | Investors | |
|---|---|---|---|---|---|---|---|
| 2026-09-09 | D/A ·current | 506(b) | — | $410.0M | — | 63 | EDGAR ↗ |
| 2026-09-09 | D/A | 506(b) | — | $410.0M | — | 63 | EDGAR ↗ |
| 2025-10-06 | D/A | 506(b) | — | $107.2M | — | 25 | EDGAR ↗ |
Related persons
Executive officers, directors and promoters, as filed. Other raises are matched by exact name and show amount sold as last reported.
- - Luma Group GP Holdings LP — Promoter, Grand Cayman, E9
- - Luma Group TopCo LLC — Promoter, Grand Cayman, E9
- - Luma Group Advisor LLC — Promoter, New York, NY
- Joshua Fink — Executive Officer / Promoter, New York, NY
-
Themasap Khan — Executive Officer / Promoter, New York, NY
2 other raises
- Integrated Biosciences, Inc. $68.4M of $100.0M · 68.4%
- Aeovian Pharmaceuticals, Inc. $55.0M of $55.0M · 100.0%
- William Ryan — Executive Officer, New York, NY
Placement agents
- No sales compensation reported — direct raise.
Source: SEC EDGAR Form D. Self-reported by the issuer. Not investment advice.